clinical

Sector Update: Health Care

Published on Mon, 04/04/2011 - 14:13
By FNNO Staff in General Interest, abt, kkr, PFE, abbott labs, abt, business, capsugel, cash, clinical, disease, drug, health, kohlberg kravis roberts, krr, medication, patient, pfe, pfizer, pharm, pill, revenue, sector, shares, treatment, Health & Pharma Report
abbott labs, abt, business, capsugel, cash, clinical, disease, drug, health, kohlberg kravis roberts, krr, medication, patient, pfe, pfizer, pharm, pill, revenue, sector, shares, treatment

Health care shares are trending higher, while Abbott Laboratories (ABT) is seeing solid gains after reporting study results. In sector news, Abbott Laboratories (ABT) today announced that data from its Endovascular Valve Edge-to-E

By FNNO Staff
fnnonline@gmail.com

Repligen Reports Disappointing Bi-Polar Drug Results, Down Over 25%

Published on Mon, 03/07/2011 - 14:16
By Stephanie Shyu in General Interest, rgen, bipolar, clinical, disorder, drug, healthcare, medical, medicine, mental health, nasdaq, placebo, repligen, rgen, shares, stock, trial, uridine, News Update

The company noted that the 50 patients enrolled through academic medical centers did show a clinically meaningful improvement, while the 125 patients enrolled at the commercial clinical trial sites did not, and it would look in to

The stock is trading down 28% at $3.53 per share.

bipolar, clinical, disorder, drug, healthcare, medical, medicine, mental health, nasdaq, placebo, repligen, rgen, shares, stock, trial, uridine

Repligen Corporation (NASDAQ:RGEN) said Monday that a mid-stage clinical trial for its bi-polar drug RG2417, an oral form of uridine, did not significantly improve symptoms compared to a placebo over an eight-week period.

By Stephanie Shyu
sshyu@fnno.com

Vertex Pharmaceuticals Shares Up Over 14% On Positive Clinical Trial Results

Published on Wed, 02/23/2011 - 15:51
By Mathieu Lloyd in General Interest, vrtx, analyst, clinical, cystic fibrosis, disease, drugs, financial, health, healthcare, lungs, market, marketing, medical, medicine, nasdaq, patients, pharma, placebo, regulatory approval, shares, stock, trial, Vertex, vrtx, vx770, News Update

The trial found patients taking the drug experienced a 17% relative improvement in their ability to force air out of their lungs in one second, a common measure of success in treating lung disease, compared with those on a placebo

Vertex's trial would have been deemed a success if it had delivered just a 4.5% improvement in the lung function test.

analyst, clinical, cystic fibrosis, disease, drugs, financial, health, healthcare, lungs, market, marketing, medical, medicine, nasdaq, patients, pharma, placebo, regulatory approval, shares, stock, trial, Vertex, vrtx, vx770

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) are up over 14% today, after it announced positive clinical trial results for its cystic fibrosis fighting drug VX-770.

By Mathieu Lloyd
mlloyd@fnno.com

Seattle Genetics Reported Mixed Q4 Results, Top Line Down 63% (SGEN)

Published on Tue, 02/08/2011 - 17:58
By Stephanie Shyu in General Interest, SGEN, analysts, cancer, clinical, consensus, disease, drug, earnings, financial, genetics, health, hodgkins, investment, loss, lymphoma, medical, nasdaq, patients, quarter, revenue, seattle, sgen, shares, studies, treatment, trial, wall street, Earnings Reports

President and Chief Executive Officer of Seattle Genetics, commented: "The strong brentuximab vedotin data we reported during the fourth quarter of 2010 highlighted an important year for Seattle Genetics, and position the company

seattle, genetics, nasdaq, sgen, earnings, quarter, shares, loss, financial, wall street, consensus, analysts, revenue, drug, health, medical, disease, patients, lymphoma, hodgkins, cancer, treatment, investment, clinical, trial, studies

Seattle Genetics (NASDAQ:SGEN) reported a Q4 loss of $0.34 per share, narrower than consensus estimates for a loss of $0.38 per share. Revenues for the quarter fell 63% year-over-year to $8.1 million, missing consensus estimates o

By Stephanie Shyu
sshyu@fnno.com

Vertex Pharma Reports Narrower-Than-Expected Q4 Loss (VRTX)

Published on Thu, 02/03/2011 - 17:39
By Stephanie Shyu in Earnings Lookback, vrtx, canada, cashflow, ceo, clinical, consensus, cystic fibrosis, drug, earnings, financial, health, hepatitis c, matt emmens, medical, nasdaq, pharma, regulatory approval, shares, telaprevir, trial, Vertex, vrtx, wall street, Earnings Reports

Chairman, President and CEO Matt Emmens said, "Vertex enters 2011 in a strong financial position as we prepare for the planned launch of telaprevir.

canada, cashflow, ceo, clinical, consensus, cystic fibrosis, drug, earnings, financial, health, hepatitis c, matt emmens, medical, nasdaq, pharma, regulatory approval, shares, telaprevir, trial, Vertex, vrtx, wall street

Vertex Pharmaceuticals (NASDAQ:VRTX) reported a Q4 loss of 90 cents per share, narrower than the consensus estimate of 93-cent per share loss. Revenue totaled $65.5 million and bested the Street estimate of $36.6 million.

By Stephanie Shyu
sshyu@fnno.com

RXi Pharmaceuticals Falls 14% After Choosing 1st RNAi Therap

Published on Fri, 12/17/2010 - 15:22
By FNN Staff in General Interest, rxii, candidate, clinical, fibrosis, gene, healthcare, medicine, pharmaceuticals, rnai, rxi, rxii, scar, study, surgery, therapeutic, treatment
candidate, clinical, fibrosis, gene, healthcare, medicine, pharmaceuticals, rnai, rxi, rxii, scar, study, surgery, therapeutic, treatment

RXi Pharmaceuticals (RXII) is down after it says it's selected its first RNAi therapeutic product candidate to advance into development. The development candidate, RXI–109, is a self-delivering RNAi compound (sd-rxRNA) that wi

By FNN Staff
root@fnn-online.com

Cytokinetics Drops 20.5% After Presenting ALS Treatment Stud

Published on Mon, 12/13/2010 - 11:39
By Anonymous in amyotrophic, clinical, cytk, cytokinetics, disease, dose, fnn, gehrig, lateral, lou, patients, sclerosis, treatment, trial
cytokinetics, cytk, clinical, trial, lou, gehrig, disease, patients, amyotrophic, lateral, sclerosis, treatment, dose, fnn

By Anonymous

EpiCept Surging 40% Pre-Market on New Analysis of Ceplene's

Published on Fri, 12/10/2010 - 09:39
By Anonymous in acute, aml, analysis, cancer, ceplene, clinical, drug, epct, epicept, eu, fda, fnn, leukemia, myeloid, patient, premarket, remission, survival, trial
epicept, epct, analysis, ceplene, survival, eu, remission, patient, acute, myeloid, leukemia, aml, cancer, fda, drug, clinical, trial, premarket, fnn

By Anonymous

What's In The News: December 10th, 2010

Published on Fri, 12/10/2010 - 08:15
By Anonymous in acquire, airlines, american, amr, argentina, ba, bec, beckman, bid, boeing, clinical, community, coulter, cyh, earnings, faa, fnn, gas, growth, health, healthcare, jets, occidental, offer, oil, oxy, pimco, sinopec, snp, tenet, test, thc
beckman, coulter, bec, clinical, test, community, health, cyh, acquire, bid, offer, tenet, healthcare, thc, faa, boeing, ba, jets, american, airlines, amr, argentina, sinopec, snp, occidental, oxy, oil, gas, pimco, earnings, growth, fnn

By Anonymous

Teva Reports Positive Study Results for MS Treatment, Advanc

Published on Thu, 12/09/2010 - 08:55
By Anonymous in acti, active, allegro, biotech, clinical, disability, drug, edss, expanded, fnn, laquinimod, ms, multiple, patients, pharmaceutical, placebo, relapse, remission, scale, sclerosis, severity, study, teva
teva, pharmaceutical, active, biotech, acti, clinical, allegro, study, multiple, sclerosis, ms, patients, drug, laquinimod, placebo, relapse, remission, expanded, disability, severity, scale, edss, fnn

By Anonymous

Latest News from FNNO

Yanzhou Coal Mining Looks to Continue to...

Yanzhou Coal Mining (NYSE:YZC) traded today at a new 52-week low of $8.43. This new lo ...

US Physical Therapy: 52-Week High Recent...

US Physical Therapy (NASDAQ:USPH) traded at a new 52-week high today of $30.42. This n ...

Universal Forest Products: The Winning S...

Shares of Universal Forest Products (NASDAQ:UFPI) traded today at $44.46, breaking its ...

Texas Roadhouse: 52-Week High Recently E...

Shares of Texas Roadhouse (NASDAQ:TXRH) traded at a new 52-week high today of $25.56. ...

Shares of Tractor Supply Rise Above Prev...

Shares of Tractor Supply (NASDAQ:TSCO) traded at a new 52-week high today of $116.86. ...

Timken Looks to Continue to Trade Above ...

Shares of Timken (NYSE:TKR) traded at a new 52-week high today of $58.86. This new hig ...

Teekay: 52-Week High Recently Eclipsed (...

Shares of Teekay (NYSE:TK) traded at a new 52-week high today of $40.95. So far today ...

Watch for Continued Gains in Shares of T...

Tenneco (NYSE:TEN) traded at a new 52-week high today of $46.76. Approximately 417,000 ...

Most Popular Video News

  •
    01:10 PM MIDWEEK MARKET WRAP UP:New Report Expected to Shakeup Libor

    From FNNO.com, this is the Financial News Network. I’m Cleo
    Stiller-Farrell and this is your Midweek Market Wrap Up. The British
    Bankers’ Association, which has the supervisory role of setting the
    influential Libor rates, announced that it would be willing to give up
    its...

    +
  • 11:04 AM What's in the News for September 26, 2012

    The Wall Street Journal reports that home prices showed their best year-to-date gains since 2005, up 5.9% through July, signaling the housing market's steady march toward recovery. Also from the Wall Street Journal, IBM (IBM) will increase its efforts to sell so-called cloud computing services...

    +
  • 11:04 AM Yahoo Makes Ken Goldman New CFO

    CEO Marissa Mayer is bringing in some more new blood to Yahoo!, tapping Ken Goldman as the company's new Chief Financial Officer. Goldman's appointment will take effect on October 22nd.

    Goldman served as CFO at his most recent employer, Fortinet, having worked at Siebel Systems, Sybase,...

    +
More